Medicare Will Be Leading Payer For Hepatitis C By 2017 – Milliman Report
This article was originally published in The Pink Sheet Daily
Commissioned by Janssen Therapeutics, the report focuses on how a number of changes in the U.S. health care environment will increase access to diagnosis and treatment for patients with hepatitis C and also change who pays for care.
You may also be interested in...
While Olysio will be priced higher than Incivek for the course of therapy, J&J has a broader strategy for use of the second-generation protease inhibitor. Market analysts are skeptical about the drug’s prospects even though it has some clear edges over the first-generation protease inhibitors for hepatitis C.
It’s not quite the rebate rule, but final reg aims for ‘a reduction in the use of rebates and other price concessions’ driven by the transparency requirement and broad definitions. PCMA warns that ‘mandating an increased level of disclosure for this information could result in higher prescription drug prices for consumers.’
Part of a broad rule that also aims to fix a coverage gap for COVID-19 vaccines, the payment policy differs from NTAP in that manufacturers of COVID therapies won’t have to formally apply and the add-on payments will not take the cost of the COVID products into account.